Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Longitudinal analysis of contrast acuity in Friedreich ataxia.

Hamedani AG, Hauser LA, Perlman S, Mathews K, Wilmot GR, Zesiewicz T, Subramony SH, Ashizawa T, Delatycki MB, Brocht A, Lynch DR.

Neurol Genet. 2018 Jul 23;4(4):e250. doi: 10.1212/NXG.0000000000000250. eCollection 2018 Aug.

2.

Impact of Mobility Device Use on Quality of Life in Children With Friedreich Ataxia.

Ejaz R, Chen S, Isaacs CJ, Carnevale A, Wilson J, George K, Delatycki MB, Perlman SL, Mathews KD, Wilmot GR, Hoyle JC, Subramony SH, Zesiewicz T, Farmer JM, Lynch DR, Yoon G.

J Child Neurol. 2018 May;33(6):397-404. doi: 10.1177/0883073818764941. Epub 2018 Apr 2.

PMID:
29607705
3.

Progression of Friedreich ataxia: quantitative characterization over 5 years.

Patel M, Isaacs CJ, Seyer L, Brigatti K, Gelbard S, Strawser C, Foerster D, Shinnick J, Schadt K, Yiu EM, Delatycki MB, Perlman S, Wilmot GR, Zesiewicz T, Mathews K, Gomez CM, Yoon G, Subramony SH, Brocht A, Farmer J, Lynch DR.

Ann Clin Transl Neurol. 2016 Jul 25;3(9):684-94. doi: 10.1002/acn3.332. eCollection 2016 Sep.

4.

Comorbid Medical Conditions in Friedreich Ataxia: Association With Inflammatory Bowel Disease and Growth Hormone Deficiency.

Shinnick JE, Schadt K, Strawser C, Wilcox N, Perlman SL, Wilmot GR, Gomez CM, Mathews KD, Yoon G, Zesiewicz T, Hoyle C, Subramony SH, Yiu EM, Delatycki MB, Brocht AF, Farmer JM, Lynch DR.

J Child Neurol. 2016 Aug;31(9):1161-5. doi: 10.1177/0883073816643408. Epub 2016 Apr 12.

PMID:
27071470
5.

Emerging therapies in Friedreich's ataxia.

Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA.

Neurodegener Dis Manag. 2016;6(1):49-65. doi: 10.2217/nmt.15.73. Review.

6.

Frataxin levels in peripheral tissue in Friedreich ataxia.

Lazaropoulos M, Dong Y, Clark E, Greeley NR, Seyer LA, Brigatti KW, Christie C, Perlman SL, Wilmot GR, Gomez CM, Mathews KD, Yoon G, Zesiewicz T, Hoyle C, Subramony SH, Brocht AF, Farmer JM, Wilson RB, Deutsch EC, Lynch DR.

Ann Clin Transl Neurol. 2015 Aug;2(8):831-42. doi: 10.1002/acn3.225. Epub 2015 Jul 1.

7.

Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study.

Ashizawa T, Figueroa KP, Perlman SL, Gomez CM, Wilmot GR, Schmahmann JD, Ying SH, Zesiewicz TA, Paulson HL, Shakkottai VG, Bushara KO, Kuo SH, Geschwind MD, Xia G, Mazzoni P, Krischer JP, Cuthbertson D, Holbert AR, Ferguson JH, Pulst SM, Subramony SH.

Orphanet J Rare Dis. 2013 Nov 13;8:177. doi: 10.1186/1750-1172-8-177.

8.

Analysis of the visual system in Friedreich ataxia.

Seyer LA, Galetta K, Wilson J, Sakai R, Perlman S, Mathews K, Wilmot GR, Gomez CM, Ravina B, Zesiewicz T, Bushara KO, Subramony SH, Ashizawa T, Delatycki MB, Brocht A, Balcer LJ, Lynch DR.

J Neurol. 2013 Sep;260(9):2362-9. doi: 10.1007/s00415-013-6978-z. Epub 2013 Jun 18.

PMID:
23775342
9.

Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants.

Regner SR, Wilcox NS, Friedman LS, Seyer LA, Schadt KA, Brigatti KW, Perlman S, Delatycki M, Wilmot GR, Gomez CM, Bushara KO, Mathews KD, Subramony SH, Ashizawa T, Ravina B, Brocht A, Farmer JM, Lynch DR.

J Child Neurol. 2012 Sep;27(9):1152-8. doi: 10.1177/0883073812448462. Epub 2012 Jun 29.

10.

FXN methylation predicts expression and clinical outcome in Friedreich ataxia.

Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, Saffery R, Galati JC, Wong NC, Craig JM, Lynch DR, Regner SR, Brocht AF, Perlman SL, Bushara KO, Gomez CM, Wilmot GR, Li L, Varley E, Delatycki MB, Sarsero JP.

Ann Neurol. 2012 Apr;71(4):487-97. doi: 10.1002/ana.22671.

PMID:
22522441
11.

Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia.

Regner SR, Lagedrost SJ, Plappert T, Paulsen EK, Friedman LS, Snyder ML, Perlman SL, Mathews KD, Wilmot GR, Schadt KA, Sutton MS, Lynch DR.

Am J Cardiol. 2012 Feb 1;109(3):401-5. doi: 10.1016/j.amjcard.2011.09.025. Epub 2011 Nov 10.

PMID:
22078220
12.

Mortality in Friedreich ataxia.

Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, Ravina B, Koeppen AH, Lynch DR.

J Neurol Sci. 2011 Aug 15;307(1-2):46-9. doi: 10.1016/j.jns.2011.05.023. Epub 2011 Jun 8.

PMID:
21652007
13.

Therapeutic interventions in the primary hereditary ataxias.

Revuelta GJ, Wilmot GR.

Curr Treat Options Neurol. 2010 Jul;12(4):257-73. doi: 10.1007/s11940-010-0075-8.

PMID:
20842586
14.

A negative electroretinogram (ERG) in a case of probable multiple system atrophy (MSA).

Barnes CS, Yan J, Wilmot GR.

Doc Ophthalmol. 2009 Jun;118(3):247-56. doi: 10.1007/s10633-008-9156-3. Epub 2008 Nov 21.

PMID:
19023607
15.

Health related quality of life measures in Friedreich Ataxia.

Epstein E, Farmer JM, Tsou A, Perlman S, Subramony SH, Gomez CM, Ashizawa T, Wilmot GR, Mathews K, Wilson RB, Balcer LJ, Lynch DR.

J Neurol Sci. 2008 Sep 15;272(1-2):123-8. doi: 10.1016/j.jns.2008.05.009. Epub 2008 Jun 20.

PMID:
18571673
16.

Antioxidant use in Friedreich ataxia.

Myers L, Farmer JM, Wilson RB, Friedman L, Tsou A, Perlman SL, Subramony SH, Gomez CM, Ashizawa T, Wilmot GR, Mathews KD, Balcer LJ, Lynch DR.

J Neurol Sci. 2008 Apr 15;267(1-2):174-6. Epub 2007 Nov 7.

17.

Measuring Friedreich ataxia: complementary features of examination and performance measures.

Lynch DR, Farmer JM, Tsou AY, Perlman S, Subramony SH, Gomez CM, Ashizawa T, Wilmot GR, Wilson RB, Balcer LJ.

Neurology. 2006 Jun 13;66(11):1711-6.

PMID:
16769945
18.

gRICH68 and gRICH70 are 2',3'-cyclic-nucleotide 3'-phosphodiesterases induced during goldfish optic nerve regeneration.

Ballestero RP, Wilmot GR, Agranoff BW, Uhler MD.

J Biol Chem. 1997 Apr 25;272(17):11479-86.

19.
20.
21.

Glutamic acid-insensitive [3H]kainic acid binding in goldfish brain.

Davis RE, Wilmot GR, Cha JH.

Brain Res. 1992 Jan 31;571(1):73-8.

Supplemental Content

Loading ...
Support Center